First report of a carbapenemase OXA-48-producing Hafnia alvei clinical isolate
Access Microbiology · 01.06.2023 · 5 (6)
DOI: 10.1099/acmi.0.000498.v3 ↗Kurz gefasst
Fallbericht in der Zeitschrift Access Microbiology, erschienen am 01.06.2023. Verfasst von Laura Sevillano und 6 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Microbiología, Hospital Universitario de La Princesa, Madrid, Spain. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Carbapenems are usually used in the treatment of infections caused by cephalosporin-resistant Enterobacterales ; however, the increase in carbapenem-resistant Enterobacterales (CRE) has become one of the most important problems in public health. Hafnia alvei is associated with intestinal and extraintestinal infections, especially in patients with any chronic disease or some type of immunosupression. H. alvei is resistant to first-generation aminopenicillins and cephalosporins owing to the β-lactamase (Amp C) in their chromosome; the only carbapenem-resistant Hafnia strain described until now was due to a lack of the OmpK36 protein that plays an important role in permeability to carbapenems. Case presentation. We present the case of a 65-year-old male diagnosed with acute lithiasic cholecystitis. Culture of the biliary prosthesis yielded a OXA-48-producing H. alvei that was identified by MALDI-TOF (matrix-assisted laser desorption/ionization-time of flight) MS. Carbapenemase production was detected by immunochromatography and confirmed by sequencing.
Conclusion
To our knowledge, this is the first report of OXA-48-producing H. alvei probably obtained by horizontal transfer from Enterobacter cloacae OXA-48 isolated in previous samples.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Servicio de Microbiología, Hospital Universitario de La Princesa, Madrid, Spain.
- Servicio de Cirugía General y Digestivo, Hospital Universitario de La Princesa, C/Diego de León, 62. 28006, Madrid, Spain.
ORCID-Profile: Laura Sevillano
Zitieren
APA
Sevillano, L., Herrera, C., Valdes, Á., de la Hoz, Á., Cardeñoso, L., Domingo, D., & Semiglia, M. A. (2023). First report of a carbapenemase OXA-48-producing Hafnia alvei clinical isolate. Access Microbiology, 5(6). https://doi.org/10.1099/acmi.0.000498.v3
Vancouver
Sevillano L, Herrera C, Valdes Á, de la Hoz Á, Cardeñoso L, Domingo D, et al. First report of a carbapenemase OXA-48-producing Hafnia alvei clinical isolate. Access Microbiology. 2023;5(6). doi:10.1099/acmi.0.000498.v3
BibTeX
@article{Sevillano2023,
author = {Sevillano, Laura and Herrera, Cristhian and Valdes, Álvaro and de la Hoz, Ángela and Cardeñoso, Laura and Domingo, Diego and Semiglia, Maria Auxiliadora},
title = {First report of a carbapenemase OXA-48-producing Hafnia alvei clinical isolate},
journal = {Access Microbiology},
year = {2023},
volume = {5},
number = {6},
doi = {10.1099/acmi.0.000498.v3}
}
EUVIMED